Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA methylation changes in leukaemia.

John R Melki1, Susan J Clark

  • 1Kanematsu Laboratories, Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia.

Seminars in Cancer Biology
|August 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA methylation reprogramming in marsupial embryos is restricted to the extraembryonic lineage.

Nature communications·2026
Same author

Interplay of the 3D genome and epigenome in androgen-driven prostate cancer.

Epigenomics·2026
Same author

Isoform-specific single-cell perturb-seq reveals distinct functions of alternative promoters in drug response.

Nucleic acids research·2026
Same author

DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer.

Clinical epigenetics·2026
Same author

DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?

Epigenomics·2025
Same author

PPARγ acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding.

Oncogene·2025
Same journal

Role of oral microbiome in cancer immunotherapy.

Seminars in cancer biology·2026
Same journal

Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

Seminars in cancer biology·2026
Same journal

Hidden architecture of resistance: The extracellular matrix in melanoma's immune landscape.

Seminars in cancer biology·2026
Same journal

Microfluidic technologies for extracellular vesicle isolation and analysis: Implications for translational applications in cancer therapy.

Seminars in cancer biology·2026
Same journal

Exploring glioblastoma microenvironment using organoids: opportunities, limitations, and emerging concepts.

Seminars in cancer biology·2026
Same journal

Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease.

Seminars in cancer biology·2026
See all related articles

Leukaemia development involves genetic and epigenetic changes. Aberrant DNA methylation, including decreased genomic 5-methylcytosine and hypermethylation of tumor suppressor genes, is crucial in hematopoietic malignancies.

Area of Science:

  • Hematology
  • Cancer Biology
  • Epigenetics

Background:

  • Leukaemogenesis is a complex, multi-step process involving genetic and phenotypic alterations in clonal cell populations.
  • While traditionally viewed as a genetic disease, epigenetic defects, particularly DNA methylation, are increasingly recognized as critical in leukaemia development.
  • Elevated DNA methyltransferase enzyme expression and aberrant methylation patterns, including global hypomethylation and specific gene hypermethylation, are observed in leukaemia.

Purpose of the Study:

  • To review the diverse DNA methylation changes occurring in haematopoietic malignancies.
  • To discuss the diagnostic and therapeutic implications of these epigenetic alterations in leukaemia.

Main Methods:

  • This is a review article, synthesizing existing research on DNA methylation in leukaemogenesis.

Related Experiment Videos

  • It examines findings related to DNA methyltransferase expression, global 5-methylcytosine levels, and CpG island methylation status in tumour suppressor genes.

    • Main Results:

    • Aberrant DNA methylation is a hallmark of leukaemia, characterized by reduced overall genomic 5-methylcytosine.
    • Hypermethylation of CpG islands in tumour suppressor genes is a common epigenetic defect contributing to leukaemic transformation.
    • These methylation changes are widespread across various haematopoietic malignancies.

    Conclusions:

    • DNA methylation plays a significant role in the pathogenesis of haematopoietic malignancies.
    • Understanding these epigenetic alterations is vital for improving leukaemia diagnosis and developing novel treatment strategies.